Top news of the week: 05.01.2022.
Companies And Industries
2021 drug approvals: In a year dominated by COVID, biopharma managed to deliver 55 new drugs
Each year, many scientists and other experts working in the biopharma industry see years of their work culminate in FDA approvals. With the COVID-19 crisis stretching into its third year, ...
Three Life Sciences Companies Plan to Ring More than New Year's Bells
Three IPO aspirants have stepped up at the start of the year, including CinCor Pharma, a clinical-stage biopharmaceutical company focused on developing its lead asset CIN-107 to treat ...
The biotech scorecard for the first quarter: 19 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter.
Executives On The Move: Changes At Genor, Tenaya And More
<p>A new secretary appointed at Genor Biopharma and promotions at Zai Lab are among recent executive changes in the industry. Meanwhile, new directors were appointed at Tenaya Therapeutics, ...
FDA Okays Pfizer/BioNTech Booster for Adolescents and a Patent-Free Vaccine
Low-income countries still struggle to get first jabs into arms. Researchers and pharma companies continue to push for low-cost vaccines and drugs worldwide.
The Drugs That Will Shape 2022
Join FirstWord Pharma PLUS editors Michael Flanagan, Virginia Li and Simon King as they discuss the drugs and companies that will shape biopharma headlines in 2022. Learn about new ...
Synthetic biology innovations that rewire human cells poised to tackle complex diseases
Let’s recognize that synthetic biology can make the impossible happen in many areas besides food production. For example, synthetic biology can produce
Robert Califf is a fervent believer in data. At the FDA, will that be enough?
Robert Califf, President Biden's nominee to lead the FDA, is driven by the need to build consensus — a tendency that may or may not serve him well at the agency.